LogoPeqSERPE
logoCabeceraNinos

Hemos leído sobre ... AIJ Sistémica

Última actualización: 21 septiembre 2022
 
AGOSTO 2022
    • Rood JE, Rezk A, Pogoriler J, Finn LS, Burnham JM, Josephson MB, Bar-Or A, Behrens EM, Canna SW.
      Improvement of Refractory Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease with Single-Agent Blockade of IL-1β and IL-18.
      J Clin Immunol. 2022 Aug 25. doi: 10.1007/s10875-022-01353-y.
      https://pubmed.ncbi.nlm.nih.gov/36006569/

    • Eveillard LA, Quartier P, Ouldali N, Bader-Meunier B, Aeschlimann F, Abasq C, et al; Groupe de recherche de la Société Française de Dermatologie Pédiatrique (SFDP); Société Francophone pour la rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP).
      Association of atypical skin manifestations at the onset of systemic juvenile idiopathic arthritis with difficult-to-treat disease: A retrospective multicenter study.
      J Am Acad Dermatol. 2022 Aug 10:S0190-9622(22)02439-2. doi: 10.1016/j.jaad.2022.07.055.
      https://pubmed.ncbi.nlm.nih.gov/35963289/

    • Gillard L, Pouchot J, Cohen-Aubart F, Koné-Paut I, Mouterde G, Michaud M, Reumaux H, Savey L, Belot A, Fautrel B, Mitrovic S; CRI (Club Rhumatismes et Inflammation).
      JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
      Rheumatology (Oxford). 2022 Aug 3:keac440. doi: 10.1093/rheumatology/keac440.
      https://pubmed.ncbi.nlm.nih.gov/35920788/

    • Zhu D, Meng J, Jia J, Wang M, Ma Y, Shi H, Sun Y, Liu H, Cheng X, Su Y, Ye J, Chi H, Liu T, Wang Z, Wan L, Zhou Z, Wang F, Chen X, Yang C, Hu Q, Teng J.
      Performance of the modified Systemic Manifestation Score for systemic juvenile idiopathic arthritis in Adult-onset Still's disease.
      Clin Rheumatol. 2022 Aug 27. doi: 10.1007/s10067-022-06340-7.
      https://pubmed.ncbi.nlm.nih.gov/36028637/

JULIO 2022
    • Binstadt BA, Nigrovic PA.
      The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis.
      Arthritis Rheumatol. 2022 Jul;74(7):1122-1131. doi: 10.1002/art.42137.
      https://pubmed.ncbi.nlm.nih.gov/35413159/

    • Chen G, Deutsch GH, Schulert GS, Zheng H, Jang S, Trapnell B, Lee PY, Macaubas C, Ho K, Schneider C, Saper VE, de Jesus AA, Krasnow MA, Grom A, Goldbach-Mansky R, Khatri P, Mellins ED, Canna SW.
      Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.
      Arthritis Rheumatol. 2022 Jul;74(7):1271-1283. doi: 10.1002/art.42099.
      https://pubmed.ncbi.nlm.nih.gov/35189047/

    • Malengier-Devlies B, Bernaerts E, Ahmadzadeh K, Filtjens J, Vandenhaute J, Boeckx B, Burton O, De Visscher A, Mitera T, Berghmans N, Verbeke G, Liston A, Lambrechts D, Proost P, Wouters C, Matthys P.
      Role for Granulocyte Colony-Stimulating Factor in Neutrophilic Extramedullary Myelopoiesis in a Murine Model of Systemic Juvenile Idiopathic Arthritis.
      Arthritis Rheumatol. 2022 Jul;74(7):1257-1270. doi: 10.1002/art.42104.
      https://pubmed.ncbi.nlm.nih.gov/35243819/

    • Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, Huppertz HI, Minden K, Haas JP, Jansson AF, Borte M, Schuetz C, Oommen P, Frosch M, Schlueter B, Richter-Unruh A, Kessel C, Hinze C,
      ittkowski H, Roth J, Foell D, Holzinger D.
      MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever.
      Rheumatology (Oxford). 2022 Jul 6;61(7):3082-3092. doi: 10.1093/rheumatology/keab729.
      https://pubmed.ncbi.nlm.nih.gov/34559193/

JUNIO 2022
    • Sukharomana M, Udomittipong K, Ruangchira-Urai R, Charuvanij S.
      Nonspecific interstitial pneumonia in refractory systemic juvenile idiopathic arthritis responded to tocilizumab treatment.
      Asian Pac J Allergy Immunol. 2022 Jun;40(2):172-176. doi: 10.12932/AP-050819-0616.
      https://pubmed.ncbi.nlm.nih.gov/31837211/

    • Ben Tekaya A, Hannech E, Saidane O, Bouden S, Rouached L, Tekaya R, Mahmoud I, Abdelmoula S, Abdelmoula L.
      Adult-Onset and Juvenile-Onset Still's Disease: A comparative study of both sides.
      Curr Rheumatol Rev. 2022 Jun 17. doi: 10.2174/1573397118666220617101447. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/35718964/

    • Sahba S, Huurnink A, Van den Berg JM, Tuitert B, Vastert SJ, Ten Tusscher GW.
      Systemic Juvenile Idiopathic Arthritis in two children; case report on clinical course, challenges in diagnosis and the role of FDG-PET/CT-scan.
      Clin Case Rep.2022 Jun 13;10(6):e05900. doi: 10.1002/ccr3.5900. eCollection 2022 Jun.
      https://pubmed.ncbi.nlm.nih.gov/35734189 

MAYO 2022
  • Vega-Fernandez P, Ting TV, Mar DA, Schapiro AH, Deluna MD, Saper VE, Grom AA, Schulert GS, Fairchild RM.
    Lung Ultrasound in Children with Systemic Juvenile Idiopathic Arthritis Associated Interstitial Lung Disease.
    Arthritis Care Res (Hoboken). 2022 May 23. doi: 10.1002/acr.24957. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/35604884/

MARZO 2022
    • Quartier P.
      Systemic Juvenile Idiopathic Arthritis/Pediatric Still's Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches.
      J Clin Med. 2022 Mar 1;11(5):1357. doi: 10.3390/jcm11051357.
      https://pubmed.ncbi.nlm.nih.gov/35268449/

    •  Ohya T, Nishimura K, Murase A, Hattori S, Ohara A, Nozawa T, Hara R, Ito S.
      Impaired Interleukin-18 signaling in Natural Killer cells from patients with Systemic Juvenile Idiopathic Arthritis.
      ACR Open Rheumatol. 2022 Mar 11. doi: 10.1002/acr2.11426. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/35275436/

    •  Liu W, Wen D, Liu Z, Wang K, Wang J.
      Erythropoiesis signature and ubiquitin-mediated proteolysis are enriched in systematic juvenile idiopathic arthritis.
      Int J Immunogenet. 2022 Mar 7. doi: 10.1111/iji.12573. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/35253998/

 
FEBRERO 2022
    • Giancane G, Papa R, Vastert S, Bagnasco F, Swart JF, Quartier P, Antón J, Kamphuis S, Sanner H, Glerup M, De Benedetti F, Tsitsami E, Remesal A, Moreno E, De Inocencio J, Myrup C, Pallotti C, Koné-Paut I, Franck-Larsson K, Malmström H, Cederholm S, Pistorio A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).
      Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry.
      J Rheumatol. 2022 Feb 1:jrheum.210563. doi: 10.3899/jrheum.210563. 
      https://pubmed.ncbi.nlm.nih.gov/35105709/

 
ENERO 2022
    • Ruscitti P, Natoli V, Consolaro A, Caorsi R, Rosina S, Giancane G, Naddei R, Di Cola I, Di Muzio C, Berardicurti O, Iacono D, Pantano I, Rozza G, Rossi S, De Stefano L, Balduzzi S, Vitale A, Caso F, Costa L, Prete M, Navarini L, Iagnocco A, Atzeni F, Guggino G, Perosa F, Cantarini L, Frediani B, Montecucco C, Ciccia F, Cipriani P, Gattorno M, Giacomelli R, Ravelli A.
      Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease.
      Rheumatology (Oxford). 2022 Jan 25:keac027. doi: 10.1093/rheumatology/keac027.
      https://pubmed.ncbi.nlm.nih.gov/35078234/

DICIEMBRE 2021
    • Ji-Won K, Mi-Hyun A, Ju-Yang J, Chang-Hee S, Hyoun-Ah K.
      An Update on the Pathogenic Role of Neutrophils in Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.
      Int J Mol Sci. 2021 Dec 2;22(23):13038. doi: 10.3390/ijms222313038.
      https://pubmed.ncbi.nlm.nih.gov/34884842/

    • Qu H, Sundberg E, Aulin C, Neog M et al.
      Immunoprofiling of active and inactive systemic juvenile idiopathic arthritis reveals distinct biomarkers: a single-center study.
      Pediatr Rheumatol Online J. 2021 Dec 28;19(1):173. doi: 10.1186/s12969-021-00660-9.
      https://pubmed.ncbi.nlm.nih.gov/34963488/
    • Wu J, Sun L, Tang X, Zheng Q, Guo L, Xu L, Li Y, Lu M.
      Effective Therapy of Tocilizumab on Systemic Juvenile Idiopathic Arthritis Associated Refractory Macrophage Activation Syndrome.
      Mod Rheumatol. 2021 Dec 31;roab119. doi: 10.1093/mr/roab119. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34971386/

    • Harel M, Fauteux-Daniel S, Girard-Guyonvarc'h C, Gabay C.
      Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases.
      Cytokine. 2021 Dec 17;150:155781. doi: 10.1016/j.cyto.2021.155781. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34923222/
    • Shimizu M.
      Macrophage activation syndrome in systemic juvenile idiopathic arthritis.
      Immunol Med. 2021 Dec;44(4):237-245. doi: 10.1080/25785826.2021.1912893. Epub 2021 May 13.
      https://pubmed.ncbi.nlm.nih.gov/33982649/

NOVIEMBRE 2021
    • Koker O, Demirkan FG, Cakmak F, Aktay Ayaz N.
      Performance of Recent PRINTO Criteria Versus Current ILAR Criteria for Systemic Juvenile Idiopathic Arthritis: A Single-Center Experience.
      Mod Rheumatol. 2021 Nov 30:roab115. doi: 10.1093/mr/roab115. Epub ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34850131/

    • Yan X, Tang W, Zhang Z, Zhang Y, Luo C, Tang X.
      Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease.
      Front Pediatr. 2021 Nov 8;9:735846. doi: 10.3389/fped.2021.735846.
      https://pubmed.ncbi.nlm.nih.gov/34820342/

 
SEPTIEMBRE 2021
    • Bullement A, Knowles ES, Langenfeld M, Diogo GR, Nazir J, Eriksson D.
      An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA).
      Open Access Rheumatol. 2021 Sep 10;13:257-266. doi: 10.2147/OARRR.S325400. eCollection 2021.
      https://pubmed.ncbi.nlm.nih.gov/34531691/

    • Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, Huppertz HI, Minden K, Haas JP, Jansson AF, Borte M, Schuetz C, Oommen P, Frosch M, Schlueter B, Richter-Unruh A, Kessel C, Hinze C, Wittkowski H, Roth J, Foell D, Holzinger D.
      MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever.
      Rheumatology (Oxford). 2021 Sep 24:keab729. doi: 10.1093/rheumatology/keab729. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34559193/

    • Ren Y, Labinsky H, Palmowski A, Bäcker H, Müller M, Kienzle.
      Altered molecular pathways and prognostic markers in active systemic juvenile idiopathic arthritis: integrated bioinformatic analysis
      Bosn J Basic Med Sci. 2021 Sep 3. doi: 10.17305/bjbms.2021.6016. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34480465/

AGOSTO 2021
    • Verweyen EL, Schulert GS.
      Interfering with Interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).
      Rheumatology (Oxford). 2021 Aug 30:keab673. doi: 10.1093/rheumatology/keab673. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34459891/

    • De Matteis A, Bracaglia C, Marafon DP, Piscitelli AL, Alessio M, Naddei R, et al.
      Canakinumab in Systemic Juvenile Idiopathic Arthritis: real life data from a retrospective Italian cohort.
      Rheumatology (Oxford). 2021 Aug 3:keab619. doi: 10.1093/rheumatology/keab619. Online ahead of print.
      https://pubmed.ncbi.nlm.nih.gov/34343275/

    • Zhou M, Guo R, Wang YF, Yang W, Li R, Lu L.
      Application of Weighted Gene Coexpression Network Analysis to Identify Key Modules and Hub Genes in Systemic Juvenile Idiopathic Arthritis.
      Biomed Res Int. 2021 Aug 13;2021:9957569. doi: 10.1155/2021/9957569.
      https://pubmed.ncbi.nlm.nih.gov/34435051/

    • Cai L, Zhang C, Wu J, Zhou W, Chen T.
      Unbalanced expression of membrane-bound and soluble programmed cell death 1 and programmed cell death ligand 1 in systemic juvenile idiopathic arthritis
      Clin Immunol. 2021 Aug;229:108800. doi: 10.1016/j.clim.2021.108800.
      https://pubmed.ncbi.nlm.nih.gov/34289424/

    • Worley E, Li W, Jones JT.
      Atypical Presentation of Systemic Arthritis in a Toddler with Down Syndrome.
      Case Rep Pediatr. 2021 Aug 11;2021:6567770. doi: 10.1155/2021/6567770.
      https://pubmed.ncbi.nlm.nih.gov/34422425/

JULIO 2021
    • Verweyen EL, Pickering A, Grom AA, Schulert GS.
      Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis.
      Arthritis Rheumatol. 2021 Jul;73(7):1334-1340. doi: 10.1002/art.41640. Epub 2021 May 31. PMID: 33452871; PMCID: PMC8238800.
      https://pubmed.ncbi.nlm.nih.gov/33452871/

 
JUNIO 2021
    • Manuela Pardeo, Marianna Nicoletta Rossi, Denise Pires Marafon et al
      Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis.
      Arthritis Rheumatol. 2021 Jun;73(6):1053-1061. doi: 10.1002/art.41612. Epub 2021 May 2.
      https://pubmed.ncbi.nlm.nih.gov/33615724/

 
ENERO 2021
    • JVerweyen EL, Pickering A, Grom AA, Schulert GS.
      SDistinct gene expression signatures characterize strong clinical responders vs non-responders to Canakinumab in children with sJIA.
      Arthritis Rheumatol. 2021 Jan 16. doi: 10.1002/art.41640. Epub ahead of print. PMID: 33452871.
      https://pubmed.ncbi.nlm.nih.gov/33452871/

DICIEMBRE 2020
    • Jiang H, Zhu M, Wang H, Liu H.
      Suppression of lncRNA MALAT1 reduces pro-inflammatory cytokines production by regulating miR-150-5p/ZBTB4 axis through JAK/STAT signal pathway in systemic juvenile idiopathic arthritis.
      Cytokine. 2020 Dec 16;138:155397
      https://pubmed.ncbi.nlm.nih.gov/33341002/

    • Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, Schneider R, Wulffraat NM, Chasnyk V, Tirosh I, Kallinich T, Kuemmerle-Deschner J, Wouters C, Lauwerys B, Nikishina I, Trachana M, Vougiouka O, Martini A, Lovell DJ, Levy J, Vritzali E, Ruperto N; Paediatric Rheumatology International Trials Organisation, the Pediatric Rheumatology Collaborative Study Group.
      Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
      Arthritis Rheumatol. 2020 Dec;72(12):2147-2158
      https://pubmed.ncbi.nlm.nih.gov/32648697/

    • Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
      Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
      Pediatr Res. 2020 Dec;88(6):934-939
      https://pubmed.ncbi.nlm.nih.gov/32184444/

NOVIEMBRE 2020
  • Atemnkeng Ntam V, Klein A, Horneff G.
    Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry.
    Expert Opin Drug Saf. 2020 Nov 18:1-8.
    https://pubmed.ncbi.nlm.nih.gov/33148061/
  • Sag E, Keskin A, Atalay E, Demir S, Cuceoglu MK, Akca UK, Batu ED, Bilginer Y, Ozen S.
    Performances of the "MS-score" and "HScore" in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients.
    Rheumatol Int. 2020 Nov 19. doi: 10.1007/s00296-020-04750-x.
    https://pubmed.ncbi.nlm.nih.gov/33215249/
  • Jung JY, Kim JW, Suh CH, Kim HA.
    Roles of Interactions Between Toll-Like Receptors and Their Endogenous Ligands in the Pathogenesis of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease.
    Front Immunol. 2020 Nov 5;11:583513 doi: 10.3389/fimmu.2020.583513.
    https://pubmed.ncbi.nlm.nih.gov/33224145/
  • Mizuta M, Shimizu M, Inoue N, Ikawa Y, Nakagishi Y, Yasuoka R, Iwata N, Yachie A.
    Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2020 Nov 17:keaa634. doi: 10.1093/rheumatology/keaa634.
    https://pubmed.ncbi.nlm.nih.gov/33200207/
 
SEPTIEMBRE 2020
  • Silva JR, Brito I.
    Systemic juvenile idiopathic arthritis versus adult-onset Still´s disease: the pertinence of changing the current classification criterio
    Acta Reumatol Port. 2020 Apr-Jun;45(2):150-151.
    https://pubmed.ncbi.nlm.nih.gov/32895357/

  • Malattia C, Ruperto N, Pederzoli S, Palmisani E, Pistorio A, Wouters C, Dolezalova P, Flato B, Garay S, Giancane G, Wells C, Douglass W, Brunner HI, De Benedetti F, Ravelli A; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
    Arthritis Res Ther. 2020 Sep 10;22(1):211. doi: 10.1186/s13075-020-02303-y
    https://pubmed.ncbi.nlm.nih.gov/32912276/

  • Kittiratchakool N, Kulpokin D, Chanjam C, Vilaiyuk S, Charuvanij S, Phongsamart G, Khaosut P, Tanya M, Nanagara R, Nantapaisarn S, Leelahavarong P.
    Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand
    J Rheumatol. 2020 Sep 15:jrheum.200437. doi: 10.3899/jrheum.200437. Online ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32933962/

AGOSTO 2020
  • Tibaldi J, Pistorio A, Aldera E, Puzone L, El Miedany Y, Pal P, Giri PP, De H, Khubchandani R, Chavan PP, Vilaiyuk S, Lerkvaleekul B, Yamsuwan J, Sabui TK, Datta P, Pardeo M, Bracaglia C, Sawhney S, Mittal S, Hassan WA, Elderiny GF, Abu-Zaid MH, Eissa M, Sztajnbok F, das Neves Sztajnbok FC, Russo R, Katsicas MM, Cimaz R, Marrani E, Alexeeva E, Dvoryakovskaya TM, Alsuweiti MO, Alzyoud RM, Kostik M, Chikova I, Minoia F, Filocamo G, Farag Y, Lotfy H, Nasef SI, Al-Mayouf SM, Maggio MC, Magalhaes CS, Gallizzi R, Conti G, Shimizu M, Civino A, Felici E, Giancane G, Ruperto N, Consolaro A, Ravelli A.
    Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2020 Aug 23:keaa240. doi: 10.1093/rheumatology/keaa240.
    https://pubmed.ncbi.nlm.nih.gov/32829413/
  • Quartier P, Alexeeva E, Tamàs C, Chasnyk V, Wulffraat N, Palmblad K, Wouters C, Brunner H, Marzan K, Schneider R, Horneff G, Martini A, Anton J, Wei X, Slade A, Ruperto N, Abrams K; Pediatric Rheumatology International Trials Organization (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open-label, Randomized Phase IIIb/IV Study
    Arthritis Rheumatol. 2020 Aug 11. doi: 10.1002/art.41488.
    https://pubmed.ncbi.nlm.nih.gov/32783351/
  • Prada-Medina CA, Peron JPS, Nakaya HI.
    Immature neutrophil signature associated with the sexual dimorphism of systemic juvenile idiopathic arthritis
    J Leukoc Biol. 2020 Aug 13. doi: 10.1002/JLB.6MA0720-015RR.
    https://pubmed.ncbi.nlm.nih.gov/32794262/
  • Murray GM, Vastert SJ, Ramanan AV.
    Aiming high: quantifying inflammation in systemic onset juvenile idiopathic arthritis (sJIA), a multi-faceted and complex inflammatory disease.
    Rheumatology (Oxford). 2020 Aug 26:keaa394. doi: 10.1093/rheumatology/keaa394.
    https://pubmed.ncbi.nlm.nih.gov/32844227/
 
JULIO 2020
  • Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, Schneider R, Wulffraat NM, Chasnyk V, Tirosh I, Kallinich T, Kuemmerle-Deschner J, Wouters C, Lauwerys B, Nikishina I, Trachana M, Vougiouka O, Martini A, Lovell DJ, Levy J, Vritzali E, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Efficacy and Safety of Canakinumab in sJIA Patients with and without Fever at Baseline: Results from an Open-label, Active Treatment Extension Study.
    Arthritis Rheumatol. 2020 Jul 10. doi: 10.1002/art.41436. Epub ahead of print.
    https://pubmed.ncbi.nlm.nih.gov/32648697/
 
 
JUNIO 2020
  • Jørgensen SE, Christiansen M, Høst C, Glerup M, Mahler B, Lausten MM, Gad HH, Hartmann R, Herlin T, Mogensen TH.
    Systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome due to a CASP1 variant causing inflammasome hyperactivation.
    Rheumatology (Oxford). 2020 Jun 18:keaa242. doi: 10.1093/rheumatology/keaa242.
    https://pubmed.ncbi.nlm.nih.gov/32556329/
  • Nishimura K, Hara R, Umebayashi H, Takei S, Iwata N, Imagawa T, Shimizu M, Tomiita M, Seko N, Kitawaki T, Yokota S.
    Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label Phase III study in Japanese patients.
    Mod Rheumatol. 2020 Jun 17:1-24. doi: 10.1080/14397595.2020.1783163.
    https://pubmed.ncbi.nlm.nih.gov/32552266/
  • Maller J, Fox E, Park KT, Paul SS, Baszis K, Borocco C, Prahalad S, Quartier P, Reinhardt A, Schonenberg-Meinema D, Shipman L, Terreri MT, Simard J, Lavi I, Chalom E, Hsu J, Zisman D, Mellins ED; CARRA Legacy Registry Investigators.
    Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol. 2020 Jun 15:jrheum.200230. doi: 10.3899/jrheum.200230.
    https://pubmed.ncbi.nlm.nih.gov/32541073/
  • Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, Fuhlbrigge R, Goldmuntz E, Kingsbury DJ, Patty-Resk C, Mintz S, Onel K, Rider LG, Schneider R, Watts A, von Scheven E, Lovell DJ, Beukelman T; PRCSG Advisory Council, the CARRA Registry Investigators.
    New medications are needed for children with juvenile idiopathic arthritis.
    Arthritis Rheumatol. 2020 Jun 10. doi: 10.1002/art.41390
    https://pubmed.ncbi.nlm.nih.gov/32524767/
 
MAYO 2020
  • Zhong L, Wang W, Li J, Ma M, Gou L, Wang C, Yu Z, Zhang T, Dong Y, Wei Q, Song H.
    The association of MEFV gene mutations with the disease risk and severity of systemic juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2020 May 12;18(1):38.
    https://doi.org/10.1186/s12969-020-00427-8
 
 
MARZO 2020
  • Henderson LA, Hoyt KJ, Lee PY, Rao DA, Jonsson AH, Nguyen JP, Rutherford K, Julé AM, Charbonnier LM, Case S, Chang MH, Cohen EM, Dedeoglu F, Fuhlbrigge RC, Halyabar O, Hazen MM, Janssen E, Kim S, Lo J, Lo MS, Meidan E, Son MBF, Sundel RP, Stoll ML, Nusbaum C, Lederer JA, Chatila TA, Nigrovic PA.
    Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis.
    JCI Insight. 2020 Mar 26;5(6). pii: 132508. doi: 10.1172/jci.insight.132508.
    https://www.ncbi.nlm.nih.gov/pubmed/32213704
  • Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy.
    Pediatr Res. 2020 Mar 17. doi: 10.1038/s41390-020-0843-4. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/32184444
 
FEBRERO 2020
  • Maritsi DN, Vougiouka O, Eleftheriou D.
    Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol. 2020 Feb 15. pii: jrheum.190011. doi: 10.3899/jrheum.190011.
    https://www.ncbi.nlm.nih.gov/pubmed/32062604
  • Bader-Meunier B, Hadchouel A, Berteloot L, Polivka L, Béziat V, Casanova JL, Lévy R.
    Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report.
    Ann Rheum Dis. 2020 Feb 13. pii: annrheumdis-2020-216983. doi: 10.1136/annrheumdis-2020-216983.
    https://www.ncbi.nlm.nih.gov/pubmed/32054604
 
 
ENERO 2020
  • Aljaberi N, Tronconi E, Schulert G, Grom AA, Lovell DJ, Huggins JL, Henrickson M, Brunner HI.
    The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis.
    Pediatr Rheumatol Online J. 2020 Jan 16;18(1):7. doi: 10.1186/s12969-020-0398-2.
    https://www.ncbi.nlm.nih.gov/pubmed/31948488
  • Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, Hoyt KJ, Blaustein RB, Wactor A, Do T, Halyabar O, Chang MH, Dedeoglu F, Case SM, Meidan E, Lo MS, Sundel RP, Richardson ET, Newburger JW, Hershfield MS, Son MB, Henderson LA, Nigrovic PA.
    Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.
    Ann Rheum Dis. 2020 Feb;79(2):225-231. doi: 10.1136/annrheumdis-2019-216030. Epub 2019 Nov 9.
    https://www.ncbi.nlm.nih.gov/pubmed/31707357
DICIEMBRE 2019
  • Klein A, Klotsche J, Hügle B, Minden K, Hospach A, Weller-Heinemann F, Schwarz T, Dressler F, Trauzeddel R, Hufnagel M, Foeldvari I, Borte M, Kuemmerle-Deschner J, Brunner J, Oommen PT, Föll D, Tenbrock K, Urban A, Horneff G.
    Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry.
    Rheumatology (Oxford). 2019 Dec 17. pii: kez577. doi: 10.1093/rheumatology/kez577.
    https://www.ncbi.nlm.nih.gov/pubmed/31846042
  • Colafrancesco S, Manara M, Bortoluzzi A, Serban T, Bianchi G, Cantarini L, Ciccia F, Dagna L, Govoni M, Montecucco C, Priori R, Ravelli A, Sfriso P, Sinigaglia L; AOSD Consensus Group.
    Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
    Arthritis Res Ther. 2019 Dec 11;21(1):275. doi: 10.1186/s13075-019-2021-9.
    https://www.ncbi.nlm.nih.gov/pubmed/31829244
OCTUBRE 2019
  • Hinze C, Fuehner S, Kessel C, Wittkowski H, Lainka E, Baehr M, Hügle B, Haas JP, Ganser G, Weißbarth-Riedel E, Jansson A, Foell D.
    Impact of IL1RN variants on response to interleukin-1 blocking therapy in systemic juvenile idiopathic arthritis
    Arthritis Rheumatol. 2019 Oct 10. doi: 10.1002/art.41130. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31599092
 
SEPTIEMBRE 2019
  • Saper VE, Chen G, Deutsch GH, Guillerman RP, Birgmeier J, Jagadeesh K, Canna S, Schulert G, Deterding R, Xu J, Leung AN, Bouzoubaa L, Abulaban K, Baszis K, Behrens EM, Birmingham J, Casey A, Cidon M, Cron RQ, De A, De Benedetti F, Ferguson I, Fishman MP, Goodman SI, Graham TB, Grom AA, Haines K, Hazen M, Henderson LA, Ho A, Ibarra M, Inman CJ, Jerath R, Khawaja K, Kingsbury DJ, Klein-Gitelman M, Lai K, Lapidus S, Lin C, Lin J, Liptzin DR, Milojevic D, Mombourquette J, Onel K, Ozen S, Perez M, Phillippi K, Prahalad S, Radhakrishna S, Reinhardt A, Riskalla M, Rosenwasser N, Roth J, Schneider R, Schonenberg-Meinema D, Shenoi S, Smith JA, Sönmez HE, Stoll ML, Towe C, Vargas SO, Vehe RK, Young LR, Yang J, Desai T, Balise R, Lu Y, Tian L, Bejerano G, Davis MM, Khatri P, Mellins ED; Childhood Arthritis and Rheumatology Research Alliance Registry Investigators.
    Emergent high fatality lung disease in systemic juvenile arthritis.
    Ann Rheum Dis. 2019 Sep 27. pii: annrheumdis-2019-216040. doi: 10.1136/annrheumdis-2019-216040. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31562126
  • Çakan M, Karadağ ŞG, Tanatar A, Ayaz NA.
    The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis.
    Mod Rheumatol. 2019 Sep 11:1-5. doi: 10.1080/14397595.2019.1660026. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31462146
 
AGOSTO 2019
 
JULIO 2019
  •  ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, el Idrissi A, Leek AP et al.Treatment to Target Using Recombinant Interleukin1 Receptor Antagonist as FirstLine Monotherapy in NewOnset Systemic Juvenile Idiopathic Arthritis: Results From a FiveYear FollowUp Study
    Arthritis Rheumatol. 2019 Jul;71(7):1163-1173.
    https://onlinelibrary.wiley.com/doi/10.1002/art.40865
  • Shenoi S, Nanda K, Schulert GS, Bohnsack JF, Cooper AM, Edghill B, Gillispie-Taylor MC, Goldberg B, Halyabar O, Mason TG, Ronis T, Schneider R, Vehe RK, Onel K; CARRA Systemic Juvenile Idiopathic Arthritis Workgroup.
    Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey.
    Pediatr Rheumatol Online J. 2019 Jul 22;17(1):48.
    https://www.ncbi.nlm.nih.gov/pubmed/31331351
  • Gupta A, Bagri NK, Tripathy SK, Barwad A, Phulware RH, Hari P.
    Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
    Rheumatol Int. 2019 Jul 4. doi: 10.1007/s00296-019-04363-z. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31273457
  • Pal P, Giri PP, Sinha R.
    Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics.
    Indian J Pediatr. 2019 Jul;86(7):590-594.
    https://www.ncbi.nlm.nih.gov/pubmed/30937723
  • Henderson LA
    A bullseye for children with Systemic Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2019 Jul;71(7):1030-1033.
    https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40867
 
JUNIO 2019
  • Ozen S, Demir S, Batu ED.
    Testing the Model for Predicting Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol. 2019 Jun 15. pii: jrheum.190238. doi: 10.3899/jrheum.190238. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31203219
 
MAYO 2019
  •  Huang Z, Lee PY, Yao X, Zheng S, Li T.
    Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.
    Pediatrics. 2019 May;143(5). pii: e20182845. doi: 10.1542/peds.2018-2845.
    https://www.ncbi.nlm.nih.gov/pubmed/30948682
 
ABRIL 2019
  • Gohar F, McArdle A, Jones M, Callan N, Hernandez B, Kessel C, Miranda-Garcia M, Lavric M, Holzinger D, Pretzer C, Lainka E, Vastert SJ, de Roock S, FitzGerald O, Pennington SR, Foell D.
    Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis
    Ann Rheum Dis. 2019 Apr 20. pii: annrheumdis-2019-215051. doi: 10.1136/annrheumdis-2019-215051. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/31005900
  • Huang Z, Lee PY, Yao X, Zheng S, Li T
    Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.
    Pediatrics. 2019 Apr 4. pii: e20182845. doi: 10.1542/peds.2018-2845. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30948682
     
  • Pal P, Giri PP, Sinha R.
    Cyclosporine in Resistant Systemic Arthritis - A Cheaper Alternative to Biologics.
    Indian J Pediatr. 2019 Apr 1. doi: 10.1007/s12098-019-02912-9. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30937723
 
MARZO 2019
  • Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ.
    Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study.
    Arthritis Rheumatol. 2019 Mar 8. doi: 10.1002/art.40865. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/30848528
  • Wang D, Chen X, Li Z.
    Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus.
    Exp Ther Med. 2019 Mar;17(3):2305-2309
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364178/
 
FEBRERO 2019
  • Shimizu M, Inoue N, Mizuta M, Nakagishi Y, Yachie A.
    Serum Leucine-Rich α2-Glycoprotein as a Biomarker for Monitoring Disease Activity in Patients with Systemic Juvenile Idiopathic Arthritis.
    J Immunol Res. 2019 Feb 4;2019:3140204. doi: 10.1155/2019/3140204. eCollection 2019.
    https://www.ncbi.nlm.nih.gov/pubmed/30863782
  • Kudela H, Drynda S, Lux A, Horneff G, Kekow J.
    Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity.
    BMC Rheumatol. 2019 Feb 28;3:4.
    https://www.ncbi.nlm.nih.gov/pubmed/30886992
 
ENERO 2019
  • Sota J, Insalaco A, Cimaz R, Alessio M, Cattalini M, Gallizzi R, Maggio MC, Lopalco G, La Torre F, Fabiani C, Pardeo M, Olivieri AN, Sfriso P, Salvarani C, Gaggiano C, Grosso S, Bracaglia C, De Benedetti F, Rigante D, Cantarini L.
    Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.
    Front Pharmacol. 2019 Jan 8;9:1526. doi: 10.3389/fphar.2018.01526. eCollection 2018.
    https://www.ncbi.nlm.nih.gov/pubmed/30670972
  • Saccomanno B, Tibaldi J, Minoia F, Bagnasco F, Pistorio A, Guariento A, Caorsi R, Consolaro A, Gattorno M, Ravelli A.
    Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
    J Rheumatol. 2019 Jan 15. pii: jrheum.180331. doi: 10.3899/jrheum.180331. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30647180
 
OCTUBRE 2018
  • Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, Foeldvari I, Zeft A, Lomax KG, Gregson J, Abma T, Campbell-Hill S, Weiss J, Patel D, Marinsek N, Wulffraat N.
    The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an internationalsurvey and retrospective chart review.
    Clin Exp Rheumatol. 2018 Sep-Oct;36(5):920-928. Epub 2018 Mar 21
    https://www.ncbi.nlm.nih.gov/pubmed/29600940
  • Feng M, Kang M, He F, Xiao Z, Liu Z, Yao H, Wu J.
    Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients
    J Transl Med. 2018 Oct 11;16(1):277. doi: 10.1186/s12967-018-1655-8.
    https://www.ncbi.nlm.nih.gov/pubmed/30305171
 
SEPTIEMBRE 2018
  • Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ.
    Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ann Rheum Dis. 2018 Sep 29. pii: annrheumdis-2018-213150. doi: 10.1136/annrheumdis-2018-213150. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30269054
  • Baris HE, Anderson E, Sozeri B, Dedeoglu F.
    Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Clin Rheumatol. 2018 Sep 20. doi: 10.1007/s10067-018-4297-6. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30238379
 
AGOSTO 2018
  • Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, Southwood TR, Thomson W, Hyrich KL; Biologics for Children with Rheumatic Diseases Study.
    Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
    Rheumatology (Oxford). 2018 Aug 21. doi: 10.1093/rheumatology/key262. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30137641
  • Lee JJY, Schneider R.
    Systemic Juvenile Idiopathic Arthritis.
    Pediatr Clin North Am. 2018 Aug;65(4):691-709. doi: 10.1016/j.pcl.2018.04.005.
    https://www.ncbi.nlm.nih.gov/pubmed/30031494
 
JUNIO 2018
  •  Li H, Abramova I, Chesoni S, Yao Q.
    Molecular genetic analysis for periodic fever syndromes: a supplemental role for the diagnosis of adult-onset Still's disease.
    Clin Rheumatol. 2018 Jun 17. doi: 10.1007/s10067-018-4178-z
    https://www.ncbi.nlm.nih.gov/pubmed/29909561
  • Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W, Verwoerd A, Foell D, Vogl T, Roth J, Leliefeld PHC, van Loosdregt J, Koenderman L, Vastert SJ, de Roock S.
    Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2018 Jun;70(6):943-956. doi: 10.1002/art.40442
    https://www.ncbi.nlm.nih.gov/pubmed/29426067
  • Schulert GS, Zhang M, Husami A, Fall N, Brunner H, Zhang K, Cron RQ, Grom AA.
    Brief Report: Novel UNC13D Intronic Variant Disrupting an NF-κB Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2018 Jun;70(6):963-970. doi: 10.1002/art.40438.
    https://www.ncbi.nlm.nih.gov/pubmed/29409136
  • Toplak N, Blazina Š, Avčin T.
    The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
    Drug Des Devel Ther. 2018 Jun 8;12:1633-1643. doi: 10.2147/DDDT.S114532
    https://www.ncbi.nlm.nih.gov/pubmed/29922038
 
MAYO 2018
  • Hügle B, Schippers A, Fischer N, Ohl K, Denecke B, Ticconi F, Vastert B, Costa IG, Haas JP, Tenbrock K.
    Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis.
    Arthritis Res Ther. 2018 May 30;20(1):98. doi: 10.1186/s13075-018-1603-2.
    https://www.ncbi.nlm.nih.gov/pubmed/29848367
  • Sakumura N, Shimizu M, Mizuta M, Inoue N, Nakagishi Y, Yachie A.
    Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
    Cytokine. 2018 May 23. pii: S1043-4666(18)30216-3. doi: 10.1016/j.cyto.2018.05.017. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29801971
 
ABRIL 2018
    • Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, Tenbrock K, Berendes R, Niehues T, Wittkowski H, Weißbarth-Riedel E, Heubner G, Oommen P, Klotsche J, Foell D, Lainka E.
      IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
      Pediatr Rheumatol Online J. 2018 Apr 5;16(1):22. doi: 10.1186/s12969-018-0236-y.
      https://www.ncbi.nlm.nih.gov/pubmed/29622022
    • Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
      Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
      Mod Rheumatol. 2018 Apr 16:1-4. doi: 10.1080/14397595.2018.1457490. [Epub ahead of print]
      https://www.ncbi.nlm.nih.gov/pubmed/29578355
 
MARZO 2018
      • Vastert SJ, Nigrovic PA.
        Toward personalized treatment for systemic juvenile idiopathic arthritis.
        Arthritis Rheumatol. 2018 Mar 23. doi: 10.1002/art.40501. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/29569852
      • Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
        Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
        Mod Rheumatol. 2018 Mar 26:1-12.
        https://www.ncbi.nlm.nih.gov/pubmed/29578355
      • Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A
        Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
        Clin Exp Rheumatol. 2018 Mar 2. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/29533755
      • Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg LE, Kimura Y; Childhood Arthritisand Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis
        Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).Consensus Treatment Plan Workgroup.
        Clin Trials. 2018 Mar 1:1740774518761367. doi: 10.1177/1740774518761367. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29542334
      • Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, Foeldvari I, Zeft A, Lomax KG, Gregson J, Abma T, Campbell-Hill S, Weiss J, Patel D, Marinsek N, Wulffraat N.
        The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review.
        Clin Exp Rheumatol. 2018 Mar 21. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29600940
      • Stringer T, Gittler J, Meehan S, Kahn P, Oza VS.
        Neutrophilic urticarial dermatosis as a presenting feature of systemic juvenile idiopathic arthritis.
        Pediatr Dermatol. 2018 Mar 25. doi: 10.1111/pde.13464. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29574969
 
FEBRERO 2018
      • Leurs A, Launay D, Terriou L, Hatron PY, Quartier P, Hachulla E.
        Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab.
        J Clin Rheumatol. 2018 Feb 27. doi: 10.1097/RHU.0000000000000716. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29485546
      • Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.
        Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
        Ann Rheum Dis. 2018 Feb 22. pii: annrheumdis-2017-212608. doi: 10.1136/annrheumdis-2017-212608. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29472362
 
ENERO 2018
    • Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, Mönkemöller K, Neudorf U, Weißbarth-Riedel E, Wittkowski H, Horneff G, Foell D; PRO-KIND SJIA project collaborators.
      Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.
      Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7. doi: 10.1186/s12969-018-0224-2.
      https://www.ncbi.nlm.nih.gov/pubmed/29357887
PATROCINADORES